Armistice Capital’s Cellectis CLLS Stock Holding History

Armistice Capital’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-800,000	Closed	-$12.5M	–	69
2019 Q2	$12.5M	Buy	800,000 +72,000	+10%	+$1.29M	0.79%	34
2019 Q1	$13.4M	Buy	728,000 +139,000	+24%	+$2.46M	0.73%	34
2018 Q4	$9.81M	Sell	589,000 -11,000	-2%	-$255K	0.74%	32
2018 Q3	$16.9M	Buy	+600,000	New	+$17.2M	1.02%	33

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Armistice Capital's CLLS Position: Q3 2019 in Review

Armistice Capital sold out of Cellectis (CLLS) in Q3 2019, closing a stake of 800,000 shares — an estimated $12.5M sold.

Armistice Capital first reported a position in CLLS in Q3 2018 and held it in 4 quarters. The position peaked at $16.9M in Q3 2018. 64 funds tracked by Wall St. Rank hold CLLS as of Q3 2019.

Armistice Capital reported no remaining Cellectis position as of Q3 2019 after selling out during the quarter.
Armistice Capital sold 800,000 Cellectis shares in Q3 2019, an estimated $12.5M.
Armistice Capital first reported a position in Cellectis in Q3 2018 and held it in 4 quarters.
Armistice Capital's Cellectis position peaked at $16.9M in Q3 2018.
64 funds tracked by Wall St. Rank held Cellectis as of Q3 2019.

Based on Armistice Capital's 13F filing for Q3 2019, filed 14 Nov 2019.